Chemistry:SD36

From HandWiki

SD36 is an experimental anticancer drug which acts as a proteolysis targeting chimera (PROTAC) against the protein STAT3, acting by targeting this protein for destruction by cell maintenance enzymes. It has been used by a Spanish group led by Mariano Barbacid,[1] as part of a combination triple therapy alongside daraxonrasib and afatinib for treatment-resistant strains of pancreatic cancer,[2] and is also widely used for research into the treatment of other cancers and the development of related drugs.[3][4][5][6][7][8][9]

See also

References

  1. ↑ "The group led by Barbacid at CNIO completely eliminates pancreatic tumours in mice with no resistance developing.". Centro Nacional de Investigaciones Oncológicas (CNIO). Madrid, Spain. 29 January 2026. https://www.cnio.es/en/news/the-group-led-by-barbacid-at-cnio-completely-eliminates-pancreatic-tumours-in-mice-with-no-resistance-developing/. 
  2. ↑ "A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance". Proceedings of the National Academy of Sciences of the United States of America 122 (49). December 2025. doi:10.1073/pnas.2523039122. PMID 41329731. 
  3. ↑ "A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo". Cancer Cell 36 (5): 498–511.e17. November 2019. doi:10.1016/j.ccell.2019.10.002. PMID 31715132. 
  4. ↑ "Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein". Journal of Medicinal Chemistry 62 (24): 11280–11300. December 2019. doi:10.1021/acs.jmedchem.9b01530. PMID 31747516. 
  5. ↑ "SD-36 promotes growth inhibition and induces apoptosis via suppression of Mcl-1 in glioma". Journal of Cellular and Molecular Medicine 25 (17): 8261–8270. September 2021. doi:10.1111/jcmm.16754. PMID 34291563. 
  6. ↑ "Selectivity through Targeted Protein Degradation (TPD)". Journal of Medicinal Chemistry 65 (12): 8113–8126. June 2022. doi:10.1021/acs.jmedchem.2c00397. PMID 35658428. 
  7. ↑ "Uncovering PROTAC Sensitivity and Efficacy by Multidimensional Proteome Profiling: A Case for STAT3". Journal of Medicinal Chemistry 67 (6): 4804–4818. March 2024. doi:10.1021/acs.jmedchem.3c02371. PMID 38466231. 
  8. ↑ "Discovery of SD-436: A Potent, Highly Selective and Efficacious STAT3 PROTAC Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression". Journal of Medicinal Chemistry 67 (22): 20495–20513. November 2024. doi:10.1021/acs.jmedchem.4c01946. PMID 39509603. 
  9. ↑ "STAT5 and STAT3 balance shapes dendritic cell function and tumour immunity". Nature 643 (8071): 519–528. July 2025. doi:10.1038/s41586-025-09000-3. PMID 40369063. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:SD36&oldid=4243597"